CDKN2基因产物表达与卵巢癌生物学行为和预后的关系

为了解ＣＤＫＮ２基因与卵巢癌发生、生物学行为和预后的关系，采用ＳＰ法免疫组织化学染色观察了该基因产物ｐ１６蛋白在卵巢癌的表达情况。发现卵巢癌中ｐ１６蛋白的阳性率低于正常卵巢、良性和交界性肿瘤（Ｐ＜０．０１）。不同组织类型和不同分化程度卵巢癌之间ｐ１６蛋白的阳性率无显著差别（Ｐ＞０．０５），Ⅰ～Ⅱ期癌的阳性率高于Ⅲ～Ⅳ期癌（Ｐ＜０．０５），ｐ１６蛋白阴性的卵巢癌患者，其累积生存率低于ｐ１６蛋白阳性者（Ｐ＜０．０１）。结果表明，ＣＤＫＮ２基因失活与卵巢癌的发生有关，ｐ１６蛋白表达缺失与卵巢癌进展和预后不良有关。

Relation of CDKN2 Gene Expression with Biologic Behavior of Ovarian Carcinoma and Prognosis

In order to examine the expression of p16 protein in ovarian carcinoma and to determine its relationship with tumor behavior,p16 protein was studied immunohistochemically on formalin fixed paraffin embedded sections. The cytoplasmic p16 protein was mainly present in normal ovaries(91.3%),benign ovarian tumors (86.5%) and borderline tumors (78.8%); while it was significantly lower in ovarian carcinoma(50.7%)as compared to levels in above mentioned tissues( P <0.01).Among ovarian carcinomas,the presence of p16 protein was not related to histological types or differentiation of the tumor( P >0 .05),while carcinomas of stage III IV exhibited lower p16 expression levels as compared with I II stages ( P <0.05), and p16 negative group showed significantly decreased survival rate than that in p16 positive group( P <0.01).These results suggest that inactivation of CDKN2 gene is involved in the carcinogenesis of ovarian carcinomas,and that deletion of p16 protein expression is implicated in tumor progression and poor prognosis.